Veterinary Medicine Research & Development, Zoetis, Inc., Kalamazoo, Michigan, USA.
J Vet Pharmacol Ther. 2022 Jul;45(4):380-384. doi: 10.1111/jvp.13065. Epub 2022 May 19.
Oclacitinib maleate (Apoquel®, Zoetis Inc.) is commonly used around the world for the control/treatment of pruritus associated with allergic dermatitis and the control/treatment of atopic dermatitis in dogs at least 12 months of age. A new flavored chewable formulation of oclacitinib has been developed where more than 90% of doses offered to dogs were freely accepted when tested in clinical trials. The objective of this study was to determine whether the new chewable formulation of oclacitinib has a similar onset of anti-pruritic activity as the original oclacitinib film-coated tablets (FCT). Twenty-one laboratory beagle dogs were randomized to treatment and received placebo, 0.4-0.6 mg/kg oclacitinib FCT or 0.4-0.6 mg/kg flavored chewable oclacitinib tablet (n = 7/group). Efficacy was measured by assessing reduction in pruritus 1-3 h post-administration of treatments. Pruritus was induced by injecting canine IL-31, intravenously (2.5 μg/kg), approximately 15 min prior to the pruritus observation window. Results from this study demonstrated both oclacitinib FCT and the flavored chewable oclacitinib tablet significantly reduced IL-31-induced pruritus within 1-3 h post-dosing compared to placebo (p = .0069 and .0113, respectively), suggesting the new formulation of oclacitinib chewable tablets works as quickly to reduce pruritus in dogs as the oclacitinib FCT.
马来酸奥昔替尼（Apoquel®，Zoetis Inc.）在世界各地常用于控制/治疗与过敏性皮炎相关的瘙痒，以及控制/治疗至少 12 个月大的犬特应性皮炎。一种新的奥昔替尼可咀嚼调味制剂已被开发出来，在临床试验中，当提供给犬的超过 90%的剂量进行测试时，这些剂量都被自由接受。本研究的目的是确定新的奥昔替尼可咀嚼制剂是否与原奥昔替尼薄膜包衣片（FCT）具有相似的止痒作用起效时间。21 只实验室比格犬随机分组接受治疗，并接受安慰剂、0.4-0.6mg/kg 奥昔替尼 FCT 或 0.4-0.6mg/kg 调味可咀嚼奥昔替尼片剂（每组 n=7）。通过评估治疗后 1-3 小时瘙痒减少来衡量疗效。瘙痒通过静脉内注射犬白细胞介素 31（2.5μg/kg）在瘙痒观察窗口前约 15 分钟诱发。这项研究的结果表明，与安慰剂相比，奥昔替尼 FCT 和调味可咀嚼奥昔替尼片剂都能在给药后 1-3 小时内显著减轻 IL-31 诱导的瘙痒（p=0.0069 和.0113），表明新的奥昔替尼可咀嚼片剂在减少犬瘙痒方面的起效速度与奥昔替尼 FCT 一样快。
